Quantcast
Last updated on April 16, 2014 at 6:49 EDT

Latest Multiple myeloma Stories

2012-06-04 09:29:06

High levels of antibody molecule linked to increased rates of death from all diseases Mayo Clinic researchers have identified an immune system deficiency whose presence shows someone is up to four times likelier to die than a person without it. The glitch involves an antibody molecule called a free light chain; people whose immune systems produce too much of the molecule are far more likely to die of a life-threatening illness such as cancer, diabetes and cardiac and respiratory disease...

2012-06-04 02:26:17

SOUTH SAN FRANCISCO, Calif. and HOUSTON, June 4, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) and The University of Texas MD Anderson Cancer Center today announced a non-exclusive research alliance for pre-clinical and clinical research to continue to understand the role that novel experimental therapies, including Onyx's carfilzomib and oprozomib, can play in the potential treatment of multiple myeloma and lymphoma. The term of the agreement extends for two years. Financial...

2012-06-04 02:24:33

CHICAGO, June 4, 2012 /PRNewswire/ -- A three-drug treatment for the blood cancer multiple myeloma provided rapid, deep and potentially durable responses, researchers report today online in Blood, the Journal of the American Society of Hematology, and yesterday, Sunday, June 3, 2012, at the American Society of Clinical Oncology's Annual Meeting in Chicago, IL, USA. The researchers, led by Andrzej J. Jakubowiak, M.D., Ph.D., professor of medicine and director of the multiple myeloma...

2012-06-04 02:24:12

WASHINGTON, June 4, 2012 /PRNewswire-USNewswire/ -- Results from a study published online today in Blood, the Journal of the American Society of Hematology (ASH), demonstrate that inclusion of carfilzomib, a novel targeted therapy for multiple myeloma, in combination with lenalidomide and low-dose dexamethasone, resulted in complete or near complete remission in a majority of patients with newly diagnosed multiple myeloma. Multiple myeloma is cancer of the plasma cells, the white blood cells...

2012-05-28 19:32:55

NASA-funded research looks to isotope analysis rather than X-ray for measurement Are your bones getting stronger or weaker? Right now, it's hard to know. Scientists at Arizona State University and NASA are taking on this medical challenge by developing and applying a technique that originated in the Earth sciences. In a new study, this technique was more sensitive in detecting bone loss than the X-ray method used today, with less risk to patients. Eventually, it may find use in clinical...

2012-05-17 05:15:41

(Ivanhoe Newswire) -- New research shows when it comes to bone-cancer-related fractures, pain can be reduced by drug treatment, but no one drug is superior. Researchers undertook a systematic review of the current evidence on bisphosphonate drugs, which are used to prevent bone damage in multiple myeloma. Severe back pain is a common symptom of multiple myeloma–a type of cancer that can cause fractures in long bones and the spine. Bisphosphonate drugs may help to reduce the...

2012-05-16 22:24:14

Scientists optimistic that targeting pathway's cellular transcription process will lead to death of multiple myeloma cells Researchers at NYU School of Medicine have identified a target for slowing the progression of multiple myeloma by using currently available drugs. Published recently in Nature Cell Biology, the study reveals a pathway that, if deactivated, may help slow the development of the disease. "We have the ability to target this pathway with drugs that already exist,"...

2012-05-16 11:15:14

In Phase III clinical trials, the treatment decreased the risk that the cancer would progress; this positive early result prompted investigators to consider a new standard of care Multiple myeloma patients are better equipped to halt progression of this blood cancer if treated with lenalidomide, or Revlimid®, following a stem cell transplant, according to a study co-authored by a physician with the Oregon Health & Science University Knight Cancer Institute. The study, published...

2012-05-16 11:07:11

Bone cancer-related fractures and pain can be reduced by drug treatment, but no one drug is superior, according to a review published in The Cochrane Library. Researchers undertook a systematic review of the current evidence on bisphosphonate drugs, which are used to prevent bone damage in multiple myeloma. Multiple myeloma is a type of cancer that grows in and on bones, and can cause fractures in long bones and the spine. Severe back pain is a common symptom. Bisphosphonate drugs may help...

2012-05-16 02:29:59

( ) ( ) ( ) SOUTH SAN FRANCISCO, Calif., May 16, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the upcoming presentations of data highlighting Nexavar® (sorafenib) tablets, Kyprolis(TM) (proposed trademark for carfilzomib) and regorafenib, a Bayer-owned compound for which Onyx will receive a royalty on global net sales. These presentations will take place at the 48th American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, 2012, in Chicago,...